Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis

National Center for Research Resources (NCRR)0 个研究点目标入组 1 人开始时间: 1991年12月1日最近更新: 2005年6月24日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方
入组人数: 1

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

OBJECTIVES: I. Determine whether parenteral relaxin improves skin tightness, Raynaud's phenomenon, digital morbidity, and digital ulcers in a patient with progressive systemic sclerosis (scleroderma).

II. Determine whether relaxin decreases collagen production by fibroblasts in vivo and cultured from skin biopsies.

详细描述

PROTOCOL OUTLINE: This is a compassionate use study. The patient is treated with subcutaneous injections of recombinant relaxin for approximately 12 months. If clinically indicated, therapy may be extended.

研究设计

研究类型: Interventional
分配方式: Non Randomized
主要目的: Treatment

入排标准

年龄范围: 0 Years 至 —（Child, Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•PROTOCOL ENTRY CRITERIA:
•-Disease Characteristics--
•Progressive systemic sclerosis (scleroderma)
•No pregnant or nursing women

排除标准

未提供

研究者

发起方

National Center for Research Resources (NCRR)

申办方类型

Nih

相似试验

已完成

2 期

Efficacy and Safety of Relaxin for the Treatment of Acute Heart FailureHeart Failure, Congestive

NCT00520806Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies1,161

已完成

2 期

Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the LungOsteosarcomaEwing Sarcoma Family TumorsMalignant Fibrous HistiocytomaSarcoma, SynovialFibrosarcomaLeiomyosarcoma

NCT00503295Oncolytics Biotech53

已完成

2 期

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the LungMetastatic or Recurrent Squamous Cell Carcinoma of the Lung

NCT00998192Oncolytics Biotech32

已完成

2 期

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic MelanomaMetastatic Melanoma

NCT00984464Oncolytics Biotech14

已完成

2 期

A Study of Reolysin For Patients With Advanced/Metastatic Breast CancerMetastatic Breast Cancer

NCT01656538Canadian Cancer Trials Group81